BPC-157 Legal Status: WADA, the FDA and the UK Position in 2026

LynxLab · 24 October 2026 · 8 min read

Where BPC-157 stands with WADA, the US FDA and the UK MHRA as of October 2026: prohibited in sport, unapproved as a medicine, and sold for research only.

Photo: Sincerely Media, Unsplash

BPC-157 sits in three different rulebooks at once. Sport bans it, the United States treats it as an unapproved drug that pharmacies may not compound, and the UK has no licence for it and polices it through medicines law, by looking at how it is sold. This post sets out each position as of 24 October 2026, with the primary documents linked, so that anyone researching bpc-157 uk suppliers knows where the lines are.

WADA has prohibited BPC-157 since 1 January 2022

The World Anti-Doping Agency published its 2022 Prohibited List on 1 October 2021. UK Anti-Doping's summary of the major changes names one new entry under S0 Non-approved Substances: "Body Protecting Compound-157 (BPC-157) has now been listed as a prohibited substance" (UKAD, 2021).

S0 is the catch-all class. It covers any pharmacological substance not dealt with elsewhere on the List that has "no current approval by any governmental regulatory health authority for human therapeutic use". It applies at all times, in and out of competition.

The ban has not lapsed. The 2027 Prohibited List, approved on 10 September 2026 and in force from 1 January 2027, still names BPC-157 as the first example under S0 and adds the word "peptides" to the class description (WADA, 2027 Prohibited List).

USADA's advisory on the 2027 changes says WADA added "peptides" to S0 because of what it calls the current "peptide craze", and reminds athletes that a peptide not named on the List may still be prohibited (USADA, 2026). A tested athlete who handles bpc 157 in any form is taking a strict-liability risk.

The FDA's 2023 category 2 decision

In the United States, BPC-157 is not an approved drug. In September 2023 the FDA placed it in category 2 of its interim compounding policy, the category for bulk substances that "may present significant safety risks", which meant compounding pharmacies could no longer prepare it under that policy (McGuire et al., 2025).

The agency's reasons are on its website. Compounded BPC-157 "may pose risk for immunogenicity for certain routes of administration", may have "complexities with regard to peptide-related impurities", and the FDA "has identified no, or only limited, safety-related information for the proposed routes of administration" (FDA, bulk substances that may present significant safety risks).

As of 24 October 2026 that page shows BPC-157 under "bulk drug substances nominated but withdrawn", with the same safety wording attached. It is not on the 503A bulks list of substances that pharmacies may compound.

What happened at the FDA in July 2026

On 23 and 24 July 2026 the FDA's Pharmacy Compounding Advisory Committee met to consider seven peptides nominated for the 503A list. BPC-157 was reviewed for a single proposed use, ulcerative colitis (FDA advisory committee calendar, 2026).

The panel narrowly voted in favour of allowing compounding of BPC-157. The BBC reported that panel member Elizabeth Rebello, a pharmacist and anaesthesiologist, voted no "because of the lack of efficacy data" and "safety concerns", while those in favour cited "the greater good" and "medical freedom" (BBC News, July 2026).

An advisory vote is not an approval. The FDA does not have to follow its committees, and a 503A listing would only permit prescription compounding; it would not make BPC-157 a licensed medicine. Health Secretary Robert F Kennedy Jr has said he wants restrictions eased, so a policy change is possible, but at the time of writing none had appeared on the FDA's compounding pages.

Anyone comparing a US compounding pharmacy with a UK supplier of research-grade bpc-157 should keep that distinction in mind. Neither route involves an approved product.

The UK position: unlicensed, sold for research

BPC-157 has no marketing authorisation from the MHRA, so it cannot be sold or advertised as a medicine in the UK. The law that decides when a product becomes a medicine is the Human Medicines Regulations 2012.

In April 2026 the Guardian reported that the MHRA was investigating UK peptide clinics and quoted the regulator: "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation under the Human Medicines Regulations 2012" (Davis and Marsh, The Guardian, 2026).

The same article quoted Lynda Scammell, the MHRA's head of borderline products: "We disregard claims that products are for 'research purposes' if it is clear that such claims are being used as an attempt to avoid medicines regulations."

That is the line a UK seller of bpc-157 has to stay on the right side of. A peptide sold as a laboratory reagent, with no claim that it treats or prevents anything in a person, is not presented as a medicine. One sold with "aids in tissue repair" on the page is, and the MHRA confirmed to the Guardian that a clinic making exactly that claim about BPC-157 was not permitted to; the clinic deleted it.

What "research use only" means for a UK buyer

It means the product is supplied for laboratory work and nothing on the listing describes an effect on a person. It does not mean the compound is approved, tested in humans or known to be safe. The US Anti-Doping Agency's page on the peptide states that because it has not been extensively studied in humans, "it is unknown if there is a safe dose" (USADA, BPC-157).

The BBC's July 2026 report put the legal position plainly: peptides such as BPC-157 "are not illegal to buy or own", but "they are not approved for human use, so are not subject to the quality controls that govern pharmaceutical manufacturing".

That last point puts the burden of quality on the seller's testing. The FDA's objection about "peptide-related impurities" applies to any synthetic peptide, which is why a batch certificate matters more for bpc-157 vials than for a licensed drug made under good manufacturing practice.

LynxLab stocks BPC-157 for research use in 5mg, 10mg and 20mg vials from £16.95, tested to 99% purity with the certificate of analysis on the product page.

Why three regulators say the same thing

Read together, WADA, the FDA and the MHRA make one case from different angles. There is no approved human use anywhere, which is what triggers S0. The human safety record is close to empty; the FDA's phrase is "no, or only limited, safety-related information". And the supply is unregulated, so purity and identity are unknown unless someone tests them.

The science behind that gap is laid out in our post on what the BPC-157 studies actually show: three decades of rat data from one group in Zagreb, three small uncontrolled human series, and a phase 2 trial that only began recruiting in February 2026.

None of this stops a UK laboratory from choosing to buy bpc-157 for legitimate research. It does mean the buyer, not a regulator, is checking what is in the vial.

What could change next

Three dates matter. The FDA may publish a compounding policy or a proposed rule following the July vote; until it does, the committee's recommendation is advisory. WADA's 2027 List takes effect on 1 January 2027 with BPC-157 still named. And the MHRA's investigation into UK clinics, reported in April 2026, has no published outcome yet.

None of those would change the status of a bpc-157 10mg vial sold for laboratory use, which sits outside the medicines framework for as long as it is sold without medicinal claims. For how the peptide is stored and why it is described as stable, see why BPC-157 is called the stable gastric pentadecapeptide.

Frequently asked questions

Is BPC-157 banned by WADA?

Yes. It has been named under S0 Non-approved Substances since the 2022 Prohibited List took effect on 1 January 2022, and it remains named in the 2027 List. S0 substances are prohibited at all times, in and out of competition.

Is BPC-157 legal in the UK?

It is not a licensed medicine and the MHRA has issued no authorisation for it. Buying or owning it is not an offence, but anyone selling it with claims that it treats injury or disease is selling an unlicensed medicine under the Human Medicines Regulations 2012.

Did the FDA ban BPC-157?

Not outright. In September 2023 the FDA placed it in category 2 of its compounding policy, barring pharmacies from compounding it, citing immunogenicity risk, impurities and a lack of safety data. In July 2026 an advisory committee voted narrowly to recommend allowing compounding, but the FDA had not acted on that vote at the time of writing.

Is BPC-157 approved anywhere in the world?

No. USADA's position is that it "is not approved for human clinical use by the U.S. Food and Drug Administration (FDA) or any other global health authority". That absence of approval anywhere is what places it in WADA's S0 class.

Can I buy BPC-157 in the UK for research?

Yes. Buying it for laboratory use is not an offence; what the MHRA polices is how a product is described and sold, and the BBC's 2026 reporting confirms such peptides are not illegal to buy or own. Labs ordering bpc 157 uk stock should expect a batch lab report, since no regulator is checking the product for them.

Sources

Research use only

BPC-157 from LynxLab

5mg, 10mg, 20mg vials from £16.95. ≥99% purity, lab report on the page. Same-day dispatch, UK stock.

Buy BPC-157

More on BPC-157

All articles · BPC-157 product page · Lab reports